StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research note published on Wednesday. The brokerage issued a sell rating on the stock.
Oragenics Stock Performance
Oragenics stock opened at $1.03 on Wednesday. The business has a 50 day moving average of $1.69. The firm has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.11 and a beta of 0.31. Oragenics has a one year low of $1.01 and a one year high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Read More
- Five stocks we like better than Oragenics
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 4/22 – 4/26
- EV Stocks and How to Profit from Them
- 3 Stocks Leading the U.S. Agriculture Comeback
- Which Wall Street Analysts are the Most Accurate?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
